ClinicalTrials.gg
CompletedNCT01844856IGNITE1Updated Jan 11, 2022Results posted

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

A Phase 3 interventional study of Eravacycline and Ertapenem in Complicated Intra-abdominal Infections, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 69 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Intraabdominal Infections with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Intraabdominal Infections · United States.

Enrollment
2nd of 24
541 · median 144
Started
2013
with 2 others
Phase 3
9 of 29
none open now
Registered
12th of 29
by date
Lead sponsor
3 of 29
Tetraphase Pharmaceuticals, Inc.

Among the 29 studies in Intraabdominal Infections with a site in United States, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 3, and was the 12th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

3 of the 29 studies in Intraabdominal Infections with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intraabdominal Infections with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).

03

Conditions studied

  • Complicated Intra-abdominal Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participant hospitalized for cIAI
  2. At least 18 years of age (and not over 65 years of age for participant in India)
  3. Evidence of a systemic inflammatory response
  4. Abdominal pain or flank pain (with or without rebound tenderness), or pain caused by cIAI that is referred to another anatomic area
  5. Able to provide
  6. If male: must agree to use an effective barrier method of during the study and for 90 days following the last dose if sexually active with a female of
  7. If female, not pregnant or nursing or, if of childbearing potential: either will commit to use at least two medically accepted, effective methods of birth control (for example, condom, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 90 days following last study drug dose or practicing sexual abstinence

Exclusion criteria

Exclusion Criteria:

  1. Unlikely to survive the 6-8 week study period
  2. Renal failure
  3. Presence or possible signs of hepatic disease
  4. condition, including known (HIV) positivity (requiring anti-retroviral therapy or with \<300), acquired immune deficiency syndrome (AIDS), organ (bone marrow) transplant recipients, and hematological . Immunosuppressive therapy, including use of high-dose (for example, >40 mg prednisone or equivalent per day for greater than 2 weeks)
  5. History of reactions to tetracyclines, carbapenems, β-lactam antibiotics or to contained in the study drug formulations
  6. Participation in any drug or device study within 30 days prior to study entry
  7. Known or suspected current Central Nervous System disorder that may predispose to seizures or lower seizure threshold
  8. Previously received eravacycline in a clinical trial
  9. Antibiotic-related exclusions:

    1. Receipt of effective antibacterial drug therapy for cIAI for a continuous duration of >24 hours during the 72-hour preceding enrollment (however, participants with documented cIAI [that is, known baseline pathogen] who have received at least 72 hours of antibiotic therapy and are considered treatment failures may be enrolled. Treatment failure is defined as persistent fever and/or clinical symptoms; or the development of a new intra-abdominal abscess after ≥72 hours of antibiotic therapy), or
    2. Receipt of ertapenem or any other carbapenem, or tigecycline for the current infection or
    3. Need for concomitant systemic antimicrobial agents other than study drug
  10. Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion or any other resuscitative measures and drug/fluid therapy at time of consent
  11. Known or suspected inflammatory bowel disease or associated visceral abscess
  12. The anticipated need for systemic antibiotics for a duration of more than 14 days
  13. Systemic malignancy that required chemotherapy, immunotherapy, radiation therapy or antineoplastic therapy within the previous 3 months or that is anticipated to begin prior to the Test-of-Cure (TOC) visit
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    Eravacycline, 1.0 mg/kg q12h

    Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.

    Drug: Eravacycline · Drug: Placebo

  • Active comparator
    Ertapenem, 1.0 g q24h

    Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.

    Drug: Ertapenem · Drug: Placebo

Interventions

  • Also known as: TP-434

  • Also known as: Invanz

  • DrugPlacebo

    Administered IV to maintain the blind.

06

What researchers measure

Primary outcomes

  1. Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population

    Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the End-of-Treatment (EOT) visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

    Time frame: TOC visit: 25-31 days after the first dose of study drug

Secondary outcomes

  1. Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Modified Intent-to-treat (MITT) Population at the TOC Visit

    Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

    Time frame: TOC visit: 25-31 days after first dose

  2. Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Clinically Evaluable (CE) Population at the TOC Visit

    Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

    Time frame: TOC visit: 25-31 days after first dose

07

Results

Posted Mar 21, 2016

Participant flow

Participant flow — Overall Study
MilestoneEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
Started270271
Received at least 1 dose of study drug270268
Completed246255
Not completed2416
Withdrew: Lost to follow-up153
Withdrew: Adverse event36
Withdrew: Withdrawal by subject32
Withdrew: Noncompliance23
Withdrew: Enterococcus resistant01
Withdrew: Inadvertently not scheduled10
Withdrew: Randomized but was a screen failure01

Outcome measures

PrimaryClinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population

Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the End-of-Treatment (EOT) visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

Time frame:
TOC visit: 25-31 days after the first dose of study drug
Reported as:
Number · participants
Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population
participantsEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
Cure191198
Failure1911
Indeterminate1017
SecondaryClinical Response of Eravacycline and Ertapenem Treatment Arms in the Modified Intent-to-treat (MITT) Population at the TOC Visit

Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

Time frame:
TOC visit: 25-31 days after first dose
Reported as:
Number · participants
Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Modified Intent-to-treat (MITT) Population at the TOC Visit
participantsEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
Cure235238
Failure1915
Indeterminate1615
SecondaryClinical Response of Eravacycline and Ertapenem Treatment Arms in the Clinically Evaluable (CE) Population at the TOC Visit

Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment was not available). Participants who were failures at the EOT visit (within 24 hours of last dose) were considered failures at the TOC visit. The number of participants with a clinical response classification of cure, failure, or indeterminate is presented.

Time frame:
TOC visit: 25-31 days after first dose
Reported as:
Number · participants
Clinical Response of Eravacycline and Ertapenem Treatment Arms in the Clinically Evaluable (CE) Population at the TOC Visit
participantsEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
Cure222225
Failure1713
Indeterminate00

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eravacycline, 1.0 mg/kg q12h—17/270 (6.3%)43/270 (15.9%)
Ertapenem, 1.0 g q24h—16/268 (6%)28/268 (10.4%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
Abdominal abscessInfections and infestations1/2702/268
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2702/268
PneumoniaInfections and infestations2/2701/268
Wound dehiscenceInjury, poisoning and procedural complications2/2701/268
Atrial fibrillationCardiac disorders0/2701/268
Cardiopulmonary failureCardiac disorders0/2701/268
Pulseless electrical activityCardiac disorders0/2701/268
Supraventricular tachycardiaCardiac disorders0/2701/268
Abdominal compartment syndromeGastrointestinal disorders0/2701/268
Colonic fistulaGastrointestinal disorders0/2701/268
Most frequent other events
Most frequent other events
EventEravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24h
NauseaGastrointestinal disorders22/2702/268
VomitingGastrointestinal disorders11/2709/268
AnaemiaBlood and lymphatic system disorders7/2709/268
PyrexiaGeneral disorders6/2708/268
PhlebitisVascular disorders8/2701/268

Baseline characteristics

All randomized participants (Intent-to-treat \[ITT\] population)

Age, Continuous
Age, Continuous(years)Eravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24hTotal
Mean54.8 ± 16.9254.8 ± 16.0954.8 ± 16.49
Sex: Female, Male
Sex: Female, Male(Participants)Eravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24hTotal
Female114108222
Male156163319
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24hTotal
Hispanic or Latino8917
Not Hispanic or Latino261262523
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Eravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24hTotal
White263260523
Black or African American134
Asian134
Other Race459
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Eravacycline, 1.0 mg/kg q12hErtapenem, 1.0 g q24hTotal
Russian Federation282452
Romania424284
United States182038
Ukraine383876
Czech Republic141731
Latvia252348
South Africa011
Bulgaria454489
Lithuania262652
Germany224
Estonia323466
08

Study locations

69 sites
  • Florence, Alabama, United States
  • Mobile, Alabama, United States
  • Glendale, California, United States
  • La Mesa, California, United States
  • Los Angeles, California, United States
  • Torrance, California, United States
  • Aurora, Illinois, United States
  • Carmel, Indiana, United States
  • Boston, Massachusetts, United States
  • Springfield, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Las Vegas, Nevada, United States
  • Camden, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Weston, Ohio, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Cordoba, Argentina
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Brno, Czechia
  • Kladno, Czechia
  • Melnik, Czechia
  • Olomouc, Czechia
  • Prague, Czechia
  • Usti nad Labem, Czechia
  • Kohtla-Jarve, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Paris, France
  • Heidelberg, Germany
  • Luebeck, Germany
  • Magdeburg, Germany
  • Daugavpils, Latvia
  • Liepaja, Latvia
  • Riga, Latvia
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Bucharest, Romania
  • Cluj-Napoca, Romania
  • Craiova, Romania
  • Timisoara, Romania
  • Kaluga, Russian Federation
  • Kemerovo, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Smolensk, Russian Federation
  • St. Petersburg, Russian Federation
  • Tomsk, Russian Federation
  • Volgograd, Russian Federation
  • Vsevolozhsk, Russian Federation
  • Benoni, South Africa
  • Johannesburg, South Africa
  • Pretoria, South Africa
  • Worcester, South Africa
  • Dnipropetrovsk, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Odesa, Ukraine
  • Uzhhorod, Ukraine
  • Zaporizhia, Ukraine
09

References and documents

Publications

  • Solomkin JS, Sway A, Lawrence K, Olesky M, Izmailyan S, Tsai L. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance. Future Microbiol. 2019 Oct;14:1293-1308. doi: 10.2217/fmb-2019-0135. Epub 2019 Oct 1. PubMed 31570004 ↗
  • Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis. 2019 Aug 30;69(6):921-929. doi: 10.1093/cid/ciy1029. PubMed 30561562 ↗
  • Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, Sutcliffe JA, Horn P. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surg. 2017 Mar 1;152(3):224-232. doi: 10.1001/jamasurg.2016.4237. PubMed 27851857 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2013
First posted
May 1, 2013
Start
Aug 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Mar 21, 2016
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01844856
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Aug 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Mar 21, 2016
Last update
Jan 11, 2022

Study contacts

Patrick T Horn, MD, PhD
study director · Tetraphase Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion